methamphetamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
1732 537-46-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • methamphetamine
  • (S)-Methamphetamine
  • methylamphetamine
  • D-Methylamphetamine
  • methamphetamine hydrochloride
  • metamfetamine
  • methamphetamine HCl
A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.
  • Molecular weight: 149.24
  • Formula: C10H15N
  • CLOGP: 1.89
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 12.03
  • ALOGS: -2.21
  • ROTB: 3
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 0 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1000 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 40 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.92 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 67 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 4.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.85 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 12 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AKT2,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK12,MAPK7,MET,NTRK2,PDK2,PDK4,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1 38
kinase-selectivity-class AKT3,AXL,BRAF,FLT3,GRK2,PDK4,PRKCD,SIK2 8
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Dec. 31, 1943 FDA RECORDATI RARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 5371.62 57.01 1182 4523 81165 90541577
Toxicity to various agents 1971.70 57.01 714 4991 287132 90335610
Completed suicide 743.11 57.01 294 5411 144764 90477978
Cardiac arrest 329.99 57.01 151 5554 104784 90517958
Respiratory arrest 320.79 57.01 108 5597 33203 90589539
Cardio-respiratory arrest 300.94 57.01 122 5583 63018 90559724
Death 255.65 57.01 218 5487 456333 90166409
Substance abuse 175.32 57.01 45 5660 5361 90617381
Substance use disorder 161.85 57.01 35 5670 1985 90620757
Prescription drug used without a prescription 119.88 57.01 30 5675 3225 90619517
Substance use 114.41 57.01 24 5681 1175 90621567
Overdose 105.79 57.01 84 5621 157625 90465117
Amphetamines positive 104.27 57.01 17 5688 199 90622543
Drug screen positive 96.49 57.01 26 5679 3731 90619011
Drug use disorder 96.02 57.01 31 5674 8312 90614430
Opiates positive 90.59 57.01 16 5689 310 90622432
Exposure to toxic agent 73.28 57.01 25 5680 7942 90614800
Substance-induced psychotic disorder 69.39 57.01 19 5686 2893 90619849
Suspected suicide 61.42 57.01 23 5682 9545 90613197
Drug dependence 61.21 57.01 32 5673 29295 90593447
Delusion of parasitosis 60.87 57.01 10 5695 123 90622619
Accidental overdose 59.44 57.01 31 5674 28242 90594500

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 9242.73 56.58 2448 7265 102323 42509299
Toxicity to various agents 3228.59 56.58 1363 8350 227773 42383849
Completed suicide 447.65 56.58 276 9437 96189 42515433
Respiratory arrest 406.52 56.58 174 9539 28250 42583372
Cardio-respiratory arrest 282.13 56.58 172 9541 58464 42553158
Overdose 262.67 56.58 206 9507 105058 42506564
Prescription drug used without a prescription 252.06 56.58 68 9645 2662 42608960
Cardiac arrest 247.30 56.58 202 9511 109118 42502504
Exposure to toxic agent 191.08 56.58 63 9650 4941 42606681
Death 189.96 56.58 363 9350 470822 42140800
Substance use disorder 152.11 56.58 54 9659 5291 42606331
Substance abuse 148.80 56.58 61 9652 8844 42602778
Intentional product misuse 120.30 56.58 105 9608 61795 42549827
Substance use 117.59 56.58 34 9679 1717 42609905
Incorrect route of product administration 110.79 56.58 69 9644 24236 42587386
Amphetamines positive 89.15 56.58 18 9695 188 42611434
Drug use disorder 84.34 56.58 43 9670 10290 42601332
Serotonin syndrome 80.69 56.58 58 9655 25787 42585835
Fatigue 79.80 56.58 5 9708 435636 42175986
Drug screen positive 78.31 56.58 31 9682 4100 42607522
Miosis 76.38 56.58 44 9669 13402 42598220
Respiratory depression 74.63 56.58 49 9664 18819 42592803
Brain oedema 70.98 56.58 45 9668 16282 42595340
Pulmonary oedema 68.50 56.58 72 9641 53200 42558422
Accidental overdose 67.27 56.58 54 9659 28276 42583346
Opiates positive 66.70 56.58 17 9696 530 42611092
Drug dependence 66.00 56.58 54 9659 29040 42582582
Pyrexia 62.80 56.58 8 9705 394034 42217588
Accident 61.76 56.58 30 9683 6473 42605149
Diarrhoea 59.33 56.58 16 9697 460833 42150789
Suspected suicide 57.08 56.58 28 9685 6171 42605451
Postmortem blood drug level 56.81 56.58 12 9701 159 42611463

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 14623.81 46.66 3532 11232 173879 110400656
Toxicity to various agents 5274.62 46.66 2055 12709 478500 110096035
Completed suicide 1119.12 46.66 574 14190 241807 110332728
Respiratory arrest 733.50 46.66 280 14484 58019 110516516
Cardio-respiratory arrest 610.79 46.66 301 14463 115535 110459000
Cardiac arrest 568.00 46.66 343 14421 196410 110378125
Death 504.70 46.66 538 14226 698331 109876204
Overdose 372.07 46.66 282 14482 233512 110341023
Prescription drug used without a prescription 368.07 46.66 95 14669 5401 110569134
Substance use disorder 296.14 46.66 85 14679 7205 110567330
Substance abuse 263.12 46.66 88 14676 12375 110562160
Exposure to toxic agent 260.43 46.66 88 14676 12770 110561765
Substance use 195.77 46.66 49 14715 2457 110572078
Intentional product misuse 186.39 46.66 149 14615 132755 110441780
Amphetamines positive 174.96 46.66 31 14733 272 110574263
Accidental overdose 163.66 46.66 96 14668 51738 110522797
Drug screen positive 158.41 46.66 51 14713 6359 110568176
Drug use disorder 158.25 46.66 67 14697 18007 110556528
Opiates positive 151.07 46.66 33 14731 906 110573629
Respiratory depression 147.22 46.66 76 14688 31925 110542610
Incorrect route of product administration 135.34 46.66 92 14672 63969 110510566
Fatigue 117.27 46.66 13 14751 1215945 109358590
Suspected suicide 109.13 46.66 49 14715 15150 110559385
Substance-induced psychotic disorder 105.39 46.66 36 14728 5388 110569147
Miosis 103.38 46.66 53 14711 21930 110552605
Pulmonary oedema 98.63 46.66 92 14672 100567 110473968
Diarrhoea 98.50 46.66 17 14747 1139488 109435047
Serotonin syndrome 92.96 46.66 71 14693 59082 110515453
Accidental poisoning 87.73 46.66 26 14738 2461 110572074
Accident 87.30 46.66 38 14726 10914 110563621
Drug dependence 85.18 46.66 63 14701 49957 110524578
Postmortem blood drug level 84.82 46.66 17 14747 303 110574232
Pulmonary congestion 83.88 46.66 52 14712 30914 110543621
Rash 83.70 46.66 7 14757 820957 109753578
Nausea 76.28 46.66 35 14729 1235655 109338880
Pyrexia 76.23 46.66 14 14750 898251 109676284
Drug ineffective 71.80 46.66 59 14705 1520481 109054054
Unresponsive to stimuli 71.69 46.66 63 14701 63727 110510808
Delusion of parasitosis 69.67 46.66 14 14750 253 110574282
Pain 69.00 46.66 21 14743 954934 109619601
Brain oedema 68.85 46.66 46 14718 31052 110543483
Dyspnoea 68.82 46.66 31 14733 1106841 109467694
Intentional overdose 66.27 46.66 85 14679 132416 110442119
Off label use 65.06 46.66 63 14701 1500122 109074413
Drug withdrawal syndrome 64.94 46.66 48 14716 38006 110536529
Arthralgia 62.27 46.66 14 14750 779618 109794917
Drug interaction 59.81 46.66 174 14590 500009 110074526
Coma 59.54 46.66 76 14688 117793 110456742
Poisoning 59.54 46.66 41 14723 29064 110545471
Pruritus 59.11 46.66 5 14759 581555 109992980
Accidental death 59.06 46.66 23 14741 4986 110569549
Asthenia 57.85 46.66 11 14753 688988 109885547
Postmortem blood drug level abnormal 57.48 46.66 14 14750 626 110573909
Anaemia 52.20 46.66 6 14758 547080 110027455
Headache 48.42 46.66 29 14735 882348 109692187
Joint swelling 47.29 46.66 3 14761 442842 110131693

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06BA03 NERVOUS SYSTEM
PSYCHOANALEPTICS
PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
Centrally acting sympathomimetics
FDA CS M0001015 Amphetamines
FDA PE N0000175372 Appetite Suppression
FDA EPC N0000175425 Amphetamine Anorectic
MeSH PA D000697 Central Nervous System Stimulants
MeSH PA D013566 Sympathomimetics
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D015259 Dopamine Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018663 Adrenergic Agents
MeSH PA D018759 Adrenergic Uptake Inhibitors
MeSH PA D018765 Dopamine Uptake Inhibitors
MeSH PA D049990 Membrane Transport Modulators
CHEBI has role CHEBI:35337 central nervous system stimulant
CHEBI has role CHEBI:35471 psychotropic drug
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:50910 neurotoxin
CHEBI has role CHEBI:78298 environmental contaminant
FDA PE N0000175651 Increased Sympathetic Activity
FDA PE N0000175729 Central Nervous System Stimulation
FDA EPC N0000175739 Central Nervous System Stimulant

Related Drugs by ATC class:

N06BA Centrally acting sympathomimetics 14 drugs
amfetaminearmodafinilatomoxetinedexamfetaminedexmethylphenidatefencamfaminfenetyllinefenozolonelisdexamfetaminemethylphenidatemodafinilpemoline show all 14 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Attention deficit hyperactivity disorder indication 406506008
Obesity indication 414916001 DOID:9970
Gilles de la Tourette's syndrome contraindication 5158005 DOID:11119
Suicidal thoughts contraindication 6471006
Dependent drug abuse contraindication 6525002
Alcoholism contraindication 7200002
Hyperammonemia contraindication 9360008
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Bipolar disorder contraindication 13746004 DOID:3312
Hepatic encephalopathy contraindication 13920009 DOID:13413
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Feeling agitated contraindication 24199005
Hyperthyroidism contraindication 34486009 DOID:7998
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Hyperactive behavior contraindication 44548000
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Anorexia nervosa contraindication 56882008 DOID:8689
Hepatic failure contraindication 59927004
Aggressive behavior contraindication 61372001
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Arteriosclerotic vascular disease contraindication 72092001
Hepatic coma contraindication 72836002 DOID:12550
Sleep apnea contraindication 73430006 DOID:0050847
Cardiomyopathy contraindication 85898001 DOID:0050700
Weight loss contraindication 89362005
Kidney disease contraindication 90708001 DOID:557
Structural disorder of heart contraindication 128599005
Seizure disorder contraindication 128613002
Motor tic disorder contraindication 230337001
Cerebrovascular accident contraindication 230690007
Mania contraindication 231494001
Disease of liver contraindication 235856003 DOID:409
Sleep automatism contraindication 247962006
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Cardiovascular event risk contraindication 395112001
Visual impairment contraindication 397540003
Respiratory insufficiency contraindication 409623005
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Porphyria contraindication 418470004
Hypertensive urgency contraindication 443482000
Acute exacerbation of asthma contraindication 708038006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.73 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium-dependent dopamine transporter Transporter INHIBITOR Ki 7.61 PDSP CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 5.08 CHEMBL
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 6.13 PDSP
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Ki 7.91 PDSP
5-hydroxytryptamine receptor 2B GPCR Ki 5 PDSP
Alpha-2B adrenergic receptor GPCR Ki 6.13 PDSP
Alpha-2C adrenergic receptor GPCR Ki 6.09 PDSP
Trace amine-associated receptor 1 GPCR AGONIST EC50 5.89 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 5.38 PDSP
Synaptic vesicular amine transporter Transporter Ki 5.61 CHEMBL
Trace amine-associated receptor 1 GPCR EC50 5.28 CHEMBL
Trace amine-associated receptor 1 GPCR EC50 6.88 CHEMBL
Trace amine-associated receptor 1 GPCR EC50 7.15 CHEMBL

External reference:

IDSource
4019821 VUID
N0000147910 NUI
D02242 KEGG_DRUG
51-57-0 SECONDARY_CAS_RN
4018483 VANDF
4019821 VANDF
C0025611 UMLSCUI
CHEBI:6809 CHEBI
B40 PDB_CHEM_ID
CHEMBL1201201 ChEMBL_ID
DB01577 DRUGBANK_ID
CHEMBL1200952 ChEMBL_ID
D008694 MESH_DESCRIPTOR_UI
10836 PUBCHEM_CID
1879 INN_ID
4803 IUPHAR_LIGAND_ID
44RAL3456C UNII
6816 RXNORM
1988 MMSL
5066 MMSL
d00805 MMSL
001797 NDDF
004722 NDDF
387329009 SNOMEDCT_US
387499002 SNOMEDCT_US
8692006 SNOMEDCT_US
44RAL3456C INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Methamphetamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-0389 TABLET 5 mg ORAL ANDA 31 sections
Methamphetamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68308-115 TABLET 5 mg ORAL ANDA 29 sections
Methamphetamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 75907-094 TABLET 5 mg ORAL ANDA 22 sections